Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 safety and immunogenicity study of Fluvirin 2012/2013 formulation in adults and elderly subjects
2011-006271-18Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated) in influenza, sponsored by Novartis. Started Apr 2012; status: completed.
02
Drugs
influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2011-006271-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006271-18.